---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-117828"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-12-03T23:59:59+00:00"
generated_at: "2026-05-16T15:16:23.835960+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# INmune Bio corrects CEO/CFO base salaries and CEO option grant in employment agreements

## Summary
- CEO David Moss base salary corrected to $454,000 per annum; option grant corrected to 750,000 shares.
- CFO Cory Ellspermann base salary corrected to $240,000 per annum.
- Amendments effective retroactively to November 26, 2025, to fix clerical errors in original agreements.

## SEC filing metadata
- accession: 0001213900-25-117828
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-12-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025117828/0001213900-25-117828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025117828/ea0268270-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-117828
- JSON: https://secwatch.observer/filing/0001213900-25-117828.json
- Plain text: https://secwatch.observer/filing/0001213900-25-117828.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.